Every DOT regulated urine drug test is a split specimen collection. That single design choice, built into 49 CFR Part 40, gives an employee a documented way to challenge a positive result without reopening the entire testing process. Employers who understand how the split works, and who set their own deadlines and payment rules to match it, avoid a lot of confusion when a driver or safety sensitive employee asks for a retest.
This guide walks through what a split collection actually is, why DOT built the requirement into the regulation, how an employee requests a test of the split, who pays, what happens if the split fails to confirm the original result, and how non-DOT employers can borrow the same structure for their own programs.
What a split specimen collection is
Under 49 CFR 40.71, every urine collection performed for a DOT drug test must be a split specimen collection. The collector pours the single urine sample the employee provides into two separate bottles in front of the employee, using one collection container, never two separate voids.
- Bottle A (primary specimen): the collector pours at least 30 mL into this bottle. It goes to the laboratory first and is what gets tested initially.
- Bottle B (split specimen): the collector pours at least 15 mL into this second bottle. It is sealed, labeled, and shipped to the lab along with Bottle A, but it is not opened or tested unless the employee requests it.
Both bottles get tamper evident seals that the employee initials, and the collector discards any leftover urine once both bottles are properly filled and sealed. The laboratory that receives the primary specimen is not authorized to open Bottle B under any circumstance except a specific redesignation scenario in the regulation.
Why DOT requires the split
The split exists to give employees a check on the accuracy of a positive, adulterated, or substituted result without forcing a brand new collection. Because Bottle B was sealed at the same time and place as Bottle A, testing it answers a narrow but important question: does an independent laboratory, working from the same original sample, confirm what the first lab found? It is not a chance to argue interpretation or dispute the science. It is a chance to verify the specimen itself.
This is also why DOT testing differs from a lot of workplace and clinical testing that only ever uses a single specimen. The split requirement is baked into the collection procedure itself, so there is no scenario in a DOT regulated test where an employee is told a retest is simply unavailable.
The employee's right to request Bottle B testing
Under 49 CFR 40.171, once the medical review officer notifies an employee of a verified positive result, or a refusal to test based on adulteration or substitution, the employee has 72 hours from that notification to request that Bottle B be tested. The request can be made verbally or in writing directly to the MRO, and once it is made within that window, it triggers the split testing requirements.
There is one important limit: there is no split specimen testing available for an invalid result. Invalid results are handled through a different process entirely.
If an employee misses the 72 hour window, the regulation still leaves a door open. The employee can present the MRO with information showing that serious injury, illness, lack of actual notice of the result, inability to reach the MRO, or another circumstance beyond their control prevented a timely request. If the MRO agrees the explanation is legitimate, the MRO must direct that the split be tested anyway, exactly as if the request had come in on time.
Once a valid request is made, the MRO must immediately notify the laboratory that tested Bottle A, directing it to forward Bottle B to a second HHS certified laboratory, and must document the date and time of the employee's request.
Who pays for split specimen testing
49 CFR 40.173 puts the responsibility for making the process happen squarely on the employer. Employers are expected to have accounts set up in advance with laboratories so that split testing can proceed without delay once an employee makes a timely request.
The regulation is specific about what employers cannot do: they cannot condition their compliance on the employee paying directly or agreeing to reimburse the cost first. If an employee is asked to cover some or all of the cost and is unwilling or unable to, the employer still has to make sure the test happens on time, even if that means the employer ends up paying for it. This is often called the employer float rule. The employer can still seek reimbursement afterward through a written company policy or a collective bargaining agreement, but that arrangement cannot be allowed to delay or block the testing itself.
What happens if Bottle B fails to reconfirm
Under 49 CFR 40.177, the second laboratory tests Bottle B for the same drug or drug metabolite that was confirmed in Bottle A, without applying the usual screening cutoff concentrations. If the second lab cannot reconfirm the presence of that drug or metabolite, it runs validity testing to try to explain why, using the same kind of validity criteria applied to a primary specimen.
When the split genuinely fails to reconfirm the original result, 49 CFR 40.201 governs the outcome: the MRO must cancel the test. In most of these situations, a new collection is not required. The regulation carves out two narrow exceptions where a recollection under direct observation is required instead: when a substituted result's split specimen shows a creatinine concentration between 2 and 5 mg/dL, or when the primary specimen had an invalid result that was never reported to the employer's designated employer representative. Outside those two situations, a cancelled test from a failed split reconfirmation is not restaged.
Testing at a second HHS certified laboratory
The second laboratory is never the same lab that tested Bottle A. Under 49 CFR 40.175, the original laboratory ships Bottle B in its original sealed bottle, along with a copy of the MRO's written request and the portion of the chain of custody form identifying what to test for, to a different HHS certified laboratory. The originating lab is barred from sending any information identifying the employee, and the regulation leaves the choice of which second laboratory to use up to the parties involved rather than dictating it.
This structure matters because it means the split test is a genuinely independent check. A different facility, working from a sealed bottle it has never seen before, either reconfirms the finding or it does not.
How this differs from a non-DOT retest
Non-DOT drug testing programs are not required to use split collections at all, and most single specimen cup based programs used for pre-employment or general workplace testing do not generate a second bottle automatically. When an employee disputes a non-DOT positive, the options usually depend entirely on what the employer's written policy says, since there is no federal regulation dictating the process the way Part 40 does for DOT testing.
Some non-DOT programs address this by using specimen cups or collection kits designed to preserve a second sample for retesting, or by contracting with a lab that offers a comparable split process on request. Without that kind of design built in ahead of time, a non-DOT employer facing a disputed result may have no independent sample left to check against, only the option of a brand new collection days or weeks later, which answers a different question than whether the original specimen was accurately tested.
Bottle A vs Bottle B at each step
| Step | Bottle A (primary) | Bottle B (split) |
|---|---|---|
| Collection | At least 30 mL poured by the collector, 49 CFR 40.71 | At least 15 mL poured by the collector, 49 CFR 40.71 |
| Initial testing | Screened and, if needed, confirmed at the first lab | Sealed and held, not opened or tested |
| Trigger for split testing | MRO verifies positive, or refusal due to adulteration or substitution | Employee requests testing within 72 hours, 49 CFR 40.171 |
| Where it goes | Stays at the first HHS certified laboratory | Forwarded to a second, different HHS certified laboratory, 49 CFR 40.175 |
| What is tested | Full drug panel and validity testing | Only the specific drug or metabolite confirmed in Bottle A, 49 CFR 40.177 |
| If results do not match | Original result stands unless cancelled by the MRO | Failure to reconfirm generally cancels the test, 49 CFR 40.201 |
| Cost | Covered under standard testing arrangement | Employer responsible for ensuring timely payment, 49 CFR 40.173 |
Practical guidance for non-DOT employers
Employers running non-DOT programs, including many hospitals, staffing agencies, and general workplace programs, can borrow the logic of the split model even without being required to. A few practical steps:
- Write a clear retest policy into the drug testing procedure before a dispute ever comes up, including a specific window for the employee to request it.
- Decide upfront who covers the cost of a confirmation or retest, and put that in writing rather than negotiating it in the moment.
- Use collection supplies and lab partners that can support a genuine second sample or a documented retest process, not just a repeat of the same cup.
- Keep the same specimen collection standard for every employee so a challenge does not turn into a fairness question about how the sample was handled.
Programs that use drug test cups built for consistent collection and clear chain of custody documentation make it easier to defend a result if an employee ever disputes it, DOT program or not.
Frequently asked questions
How long does an employee have to request a split specimen test?
Under 49 CFR 40.171, an employee has 72 hours from the time the MRO notifies them of a verified positive or a refusal to test based on adulteration or substitution to request that Bottle B be tested.
Can an employee request a split specimen test for a dilute or invalid result?
No. The regulation specifically states there is no split specimen testing available for an invalid result. Split testing applies to verified positive results and to refusals to test based on adulteration or substitution.
Who pays for testing the split specimen?
The employer is responsible for making sure split testing happens in a timely manner. Under 49 CFR 40.173, the employer cannot delay testing while waiting on the employee to pay, though the employer may seek reimbursement afterward through policy or a labor agreement.
What happens if the split specimen does not confirm the original result?
The MRO cancels the test under 49 CFR 40.201. In most cases, this does not require a new collection, except in two narrow situations involving substituted result creatinine levels or an unreported invalid primary result.
Does the same laboratory test both bottles?
No. Bottle A stays at the laboratory that performed the original testing. Bottle B is forwarded to a different, second HHS certified laboratory for independent testing.
Do non-DOT drug tests include a split specimen?
Not automatically. Split collection is a DOT requirement under Part 40. Non-DOT employers can choose to build a similar retest process into their own policy, but it is not required by federal regulation the way it is for DOT testing.
For a closer look at how the initial collection itself is handled, see our guide to the DOT urine collection procedure, and for how results move from the lab to a final verified outcome, see our explanation of the medical review officer process.
This article is general information for employers and collection sites, not legal advice. Consult qualified counsel or your DOT compliance resource for guidance specific to your program.
